These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 17571737

  • 1. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB.
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract] [Full Text] [Related]

  • 2. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
    Michor F.
    Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 10. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.
    J Clin Oncol; 2010 Apr 10; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
    Nasr R, Bazarbachi A.
    Pathol Biol (Paris); 2012 Aug 10; 60(4):239-45. PubMed ID: 22743097
    [Abstract] [Full Text] [Related]

  • 15. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M.
    Br J Haematol; 2009 Jul 10; 146(2):227-30. PubMed ID: 19545285
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
    de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrão AC, Bentes IR, Azevedo TC, Maradei-Pereira LM.
    Genet Mol Res; 2005 Dec 30; 4(4):803-11. PubMed ID: 16475128
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Imatinib resistance in CML.
    Volpe G, Panuzzo C, Ulisciani S, Cilloni D.
    Cancer Lett; 2009 Feb 08; 274(1):1-9. PubMed ID: 18653275
    [Abstract] [Full Text] [Related]

  • 20. [Chronic myeloid leukemia].
    Udvardy M.
    Orv Hetil; 2005 Feb 06; 146(6):243-7. PubMed ID: 15779811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.